Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma.
Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, García-Laraña J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menárguez J, Sabín P, Mestre MJ, Méndez M, Fresno MF, Nicolás C, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. Sánchez-Aguilera A, et al. Among authors: de la cueva p, de sevilla af. Blood. 2006 Jul 15;108(2):662-8. doi: 10.1182/blood-2005-12-5125. Epub 2006 Mar 21. Blood. 2006. PMID: 16551964 Free article.
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Rivero A, Rapado I, Tomás JF, Montalbán C, de Oña R, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, de Sevilla AF, de la Serna J, Martínez-López J. Rivero A, et al. Among authors: de sevilla af. Leuk Res. 2011 Apr;35(4):431-7. doi: 10.1016/j.leukres.2010.09.026. Epub 2010 Oct 27. Leuk Res. 2011. PMID: 21030078
Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.
Mercadal S, Climent F, Domingo-Doménech E, Oliveira A, Romagosa V, de Sevilla AF, González-Barca E. Mercadal S, et al. Among authors: de sevilla af. Clin Med Insights Blood Disord. 2013 Nov 14;6:23-7. doi: 10.4137/CMBD.S12713. eCollection 2013. Clin Med Insights Blood Disord. 2013. PMID: 25512717 Free PMC article.
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Tomás JF, et al. Among authors: de sevilla af. Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28. Leuk Lymphoma. 2011. PMID: 21275633 Clinical Trial.
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
Coll-Mulet L, Iglesias-Serret D, Santidrián AF, Cosialls AM, de Frias M, Castaño E, Campàs C, Barragán M, de Sevilla AF, Domingo A, Vassilev LT, Pons G, Gil J. Coll-Mulet L, et al. Among authors: de frias m, de sevilla af. Blood. 2006 May 15;107(10):4109-14. doi: 10.1182/blood-2005-08-3273. Epub 2006 Jan 26. Blood. 2006. PMID: 16439685 Free article.
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E, Capote FJ, Gómez-Codina J, Panizo C, Salar A, Sancho JM, López A, Briones J, Muñoz A, Encuentra M, Mercadal S, Domingo-Domenech E, de Sevilla AF; GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). González-Barca E, et al. Among authors: de sevilla af. Ann Hematol. 2021 Apr;100(4):1023-1029. doi: 10.1007/s00277-020-04056-9. Epub 2020 May 4. Ann Hematol. 2021. PMID: 32367180 Clinical Trial.
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas). González-Barca E, et al. Among authors: de sevilla af. Haematologica. 2007 Nov;92(11):1489-94. doi: 10.3324/haematol.11360. Haematologica. 2007. PMID: 18024397 Free article. Clinical Trial.
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S, Moreno C, Domingo-Doménech E, Estany C, Oriol A, Altés A, Besalduch J, Pedro C, Gardella S, Escoda L, Asensio A, Vivancos P, Galán P, de Sevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) Spain. Montoto S, et al. Among authors: de sevilla af. Haematologica. 2008 Feb;93(2):207-14. doi: 10.3324/haematol.11671. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223288 Free article. Clinical Trial.
20 results